Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

OBJECTIVE: To analyze longitudinal levels of CSF biomarkers in drug-naive patients with Parkinson disease (PD) and healthy controls (HC), examine the extent to which these biomarker changes relate to clinical measures of PD, and identify what may influence them. METHODS: CSF α-synuclein (α-syn), tot...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollenhauer, Brit, Caspell-Garcia, Chelsea J., Coffey, Christopher S., Taylor, Peggy, Shaw, Leslie M., Trojanowski, John Q., Singleton, Andy, Frasier, Mark, Marek, Kenneth, Galasko, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679418/
https://www.ncbi.nlm.nih.gov/pubmed/29030452
http://dx.doi.org/10.1212/WNL.0000000000004609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679418/
https://www.ncbi.nlm.nih.gov/pubmed/29030452
http://dx.doi.org/10.1212/WNL.0000000000004609

Ejemplares similares